Mehmet ali Coşar

Dr. Mehmet ali Coşar

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2024 in Medicina
Verified
Journal Article
Open access
PDF file
BGBirzat Emre Gölboyu
Birzat Emre Gölboyu
MEMümin Alper Erdoğan
Mümin Alper Erdoğan
MCMehmet ali Coşar
Mehmet ali Coşar
EBEzgi Balıkoğlu
Ezgi Balıkoğlu
OEOytun Erbaş
Oytun Erbaş
Background and Objectives: This study aimed to investigate the protective effect of diosmin and hesperidin in diabetic neuropathy using a rat model, focusing on their impact on nerve regeneration through the fibroblast growth factor 21 (FGF21) and galectin-3 (gal3) pathway. Materials and Methods: Forty adult male Wistar rats were used in this study. Diabetes was induced using streptozotocin (STZ), and the rats were divided into control, diabetes and saline-treated, diabetes and diosmin + hesperidin (150 mg/kg) treated, and diabetes and diosmin + hesperidin (300 mg/kg) treated groups. Electromyography (EMG) and inclined plane testing were performed to assess nerve function and motor performance. Sciatic nerve sections were examined histopathologically. Plasma levels of FGF21, galectin-3, and malondialdehyde (MDA) were measured as markers of oxidative stress and inflammation. Results: Diabetic rats treated with saline displayed reduced nerve conduction parameters and impaired motor performance compared to controls. Treatment with diosmin and hesperidin significantly improved compound muscle action potential (CMAP) amplitude, distal latency, and motor performance in a dose-dependent manner. Histopathological examination revealed decreased perineural thickness in treated groups. Additionally, treatment with diosmin and hesperidin resulted in increased plasma FGF21 levels and reduced plasma levels of galectin-3 and MDA, indicating decreased oxidative stress and inflammation. Conclusions: Diosmin and hesperidin exhibited protective effects in diabetic neuropathy by promoting nerve regeneration, enhancing nerve conduction, and improving motor performance. These effects were associated with modulation of the FGF21 and galectin-3 pathway. These findings suggest that diosmin and hesperidin may hold potential as adjunctive therapies for diabetic neuropathy.

1 January 2026 in Journal of Clinical and Analytical Medicine
Verified
Journal Article
Closed access
EBEzgi Balıkoğlu
Ezgi Balıkoğlu
MAMurat Aksun
Murat Aksun
MCMehmet ali Coşar
Mehmet ali Coşar
SGSenem Girgin
Senem Girgin
MCMensure Cakirgoz
Mensure Cakirgoz
NKNagihan Karahan
Nagihan Karahan

19 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Ahmet Salih TüzenAhmet Salih Tüzen
Ahmet Salih Tüzen
RÖRıdvan Özlük
Rıdvan Özlük
AKAyşe Rumeysa Kocatürk
Ayşe Rumeysa Kocatürk
MCMehmet ali Coşar
Mehmet ali Coşar
ZBZülfükar Bilge
Zülfükar Bilge
MAMurat Aksun
Murat Aksun
Background/Objectives: In high-volume gastrointestinal (GI) endoscopy units, the choice of opioid adjunct may influence awakening, post-anesthesia care unit (PACU) utilization, concomitant sedative requirements, and early cardiorespiratory events. Remifentanil has a rapid and predictable offset, whereas fentanyl may produce more prolonged residual effects. We compared postanesthetic recovery after remifentanil- versus fentanyl-based propofol sedation in routine clinical practice. Methods: This single-center retrospective cohort study included adults undergoing elective upper GI endoscopy, colonoscopy, or combined procedures under anesthesiologist-directed propofol-based sedation between 1 July 2025 and 31 January 2026. Sedation was administered according to an institutional protocol targeting a Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score of 2–3. Patients received either remifentanil or fentanyl as the opioid adjunct. The primary outcome was the interval from procedure completion to the first documented response to verbal command or purposeful awakening. Secondary outcomes included procedure and anesthesia durations, PACU length of stay, propofol and midazolam doses, and early respiratory and hemodynamic events. Stabilized inverse probability of treatment weighting (IPTW) was used to balance measured baseline characteristics. Results: Among 545 patients, 280 received fentanyl and 265 received remifentanil. All assessed covariates achieved acceptable balance after weighting. Median MOAA/S score was 2 [2-2] in both groups before and after IPTW adjustment, and target-range, deeper-than-target, and lighter-than-target MOAA/S categories did not differ significantly between groups. Weighted mean recovery time was shorter with remifentanil than with fentanyl (22.6 vs. 34.1 s; adjusted mean difference, −11.4 s; 95% CI, −13.4 to −9.5; p < 0.001). Remifentanil-based sedation was also associated with shorter procedure and anesthesia durations, shorter PACU length of stay, and lower propofol and midazolam doses; these findings remained significant after false discovery rate (FDR) adjustment. No respiratory, hemodynamic, or PACU adverse outcome differed significantly after multiplicity adjustment. Conclusions: Remifentanil-based propofol sedation was associated with shorter time to first purposeful response, shorter PACU stay, and lower concomitant sedative exposure than fentanyl-based sedation during routine GI endoscopy. Documented MOAA/S findings did not show a higher frequency of lighter-than-target clinically assessed sedation in the remifentanil group. These findings may reflect the combined contribution of remifentanil’s rapid offset and lower concomitant sedative exposure, but they should be interpreted as associations within a clinician-directed sedation strategy. The retrospective, nonrandomized design precludes causal or safety-equivalence conclusions.